Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Gold nanocrystals

Other · developed by Clene Nanomedicine

Phase 2 Most advanced trial (none active)

CLNN Developer

1 Registered trials

What is Gold nanocrystals?

CNM-Au8 is an oral liquid suspension of elemental gold nanocrystals in buffered water, with sodium bicarbonate as the only buffer. It is being studied in multiple sclerosis, including the chronic progressive form.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: CNM-Au8
Drug type: Other
Therapy area: Neurology
Developer: Clene Nanomedicine (CLNN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03993171	Phase 2	Multiple Sclerosis	Completed	CLNN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Sclerosis

More from Clene Nanomedicine

CNM-Au8 Phase 2/3 CNM-ZnAg Phase 2

Sources

ClinicalTrials.gov NCT03993171

Updated Oct 11, 2026. Something wrong or missing? Report it on the CLNN page.

Follow CLNN, the company behind Gold nanocrystals

See CLNN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLNN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z